Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Liabilities and Shareholders Equity (2022 - 2025)

Atara Biotherapeutics' Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $20.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 81.45% year-over-year to $20.2 million; the TTM value through Dec 2025 reached $149.3 million, down 72.05%, while the annual FY2025 figure was $20.2 million, 81.45% down from the prior year.
  • Liabilities and Shareholders Equity reached $20.2 million in Q4 2025 per ATRA's latest filing, down from $30.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $436.1 million in Q2 2022 to a low of $20.2 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 4 years is $197.8 million, with a median of $165.4 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: decreased 23.96% in 2023, then tumbled 81.45% in 2025.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $376.4 million in 2022, then tumbled by 56.03% to $165.5 million in 2023, then crashed by 34.08% to $109.1 million in 2024, then crashed by 81.45% to $20.2 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Liabilities and Shareholders Equity are $20.2 million (Q4 2025), $30.2 million (Q3 2025), and $36.9 million (Q2 2025).